Clinical Trials Logo

Advanced Colorectal Cancer clinical trials

View clinical trials related to Advanced Colorectal Cancer.

Filter by:

NCT ID: NCT06446050 Recruiting - Clinical trials for Advanced Colorectal Cancer

Chemokine and Co-stimulatory Molecule-modified Mesenchymal Stem Cells for the Treatment of Advanced Colorectal Cancer

Start date: June 21, 2023
Phase: Early Phase 1
Study type: Interventional

The aim of this study is to assess the safety and efficacy of human umbilical cord-derived allogenic mesenchymal stem cells (MSCs) engineered to express antitumor chemokine and co-stimulatory molecule. Following systemic administration, these cells are able to migrate into solid tumors such as colorectal tumors. Once enriched in the tumor, they will attract peripheral lymphocytes consisting of T and natural killer (NK) cells, and simultaneously stimulate the infiltrated lymphocytes for persistent and enhanced antitumor immunity. Thus, this MSC-based treatment provides a potentially effective and targeted immunotherapeutic strategy for tumors with unfavorable immune microenvironment and possibly poor response to immune checkpoint blockade (ICB). During this investigator-initiated trial (IIT), colorectal cancer patients will receive modified MSCs every 21 days via intravenous infusion. Increasing does will be tested in the initial cohort and an optimal dose will be chosen for the remaining patients.

NCT ID: NCT06369259 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Start date: October 31, 2024
Phase: Phase 2
Study type: Interventional

To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.

NCT ID: NCT06200363 Recruiting - Clinical trials for Advanced Colorectal Cancer

A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer

Start date: September 21, 2023
Phase: Phase 1
Study type: Interventional

This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intravenous administration of T3011 at different doses in combination with oral regorafenib in the treatment of advanced colorectal cancer.

NCT ID: NCT06199973 Recruiting - Clinical trials for Advanced Colorectal Cancer

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 in advanced colorectal cancer subjects.

NCT ID: NCT05963087 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer

Start date: August 2023
Phase: N/A
Study type: Interventional

To explore the efficacy and safety of Cetuximab in combination with dabrafenib and Tislelizumab in BRAF mutated treatment of advanced colorectal cancer

NCT ID: NCT05928312 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer

Start date: August 28, 2023
Phase: N/A
Study type: Interventional

To explore the efficacy and safety of fruquintinib combined with chemotherapy as third-line/third-line+ Treatment in advanced metastatic colorectal cancer

NCT ID: NCT05731336 Recruiting - Clinical trials for Advanced Colorectal Cancer

A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.

Start date: May 1, 2022
Phase:
Study type: Observational [Patient Registry]

The goal of this prospective observational study is to learn about the treatment decisions in advanced colorectal cancer treated with oxaliplatin and irinotecan. The main questions:1. learn about the efficacy and safety of immunotherapy or targeted drugs or other chemotherapy for patients treated with oxaliplatin and irinotecan(non-retreatment/rechallenge group,NR group). 2. learn about the efficacy and safety of oxaliplatin or irinotecan for patients treated with oxaliplatin and irinotecan (retreatment/rechallenge group, RT/RC group). 3. compare the efficacy and safety of various treatment regimens for patients treated with oxaliplatin and irinotecan. This study will only collect the clinical data of patients, without any intervention, in the treatment services. All participants will be provided written informed consent as per the Declaration of Helsinki principles.

NCT ID: NCT05495672 Recruiting - Clinical trials for Advanced Colorectal Cancer

Circulating Tumor DNA Guided Therapeutic Strategies for CRC Patients With Small Pulmonary Nodules

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

The clinical diagnosis and treatment of small pulmonary nodules (suspected to be lung metastases) in advanced colorectal cancer patients remain controversy. Previous studies have shown that tumor-informed circulating tumor DNA (ctDNA) blood testing can sensitively detect residual cancer. Postoperative ctDNA in colorectal cancer patients is a valuable biomarker to identify minimal residual disease (MRD) after radical resection, which is possibly useful in redefining the risk group of patients and guiding postoperative treatment. This study aimed to explore the clinical value of therapeutic strategies based on tumor-informed ctDNA test in advanved colorectal cancer patients with small pulmonary nodules.

NCT ID: NCT05424068 Recruiting - Clinical trials for Advanced Breast Cancer

Rehabilitation for People With Advanced Cancer

Start date: December 2, 2022
Phase: N/A
Study type: Interventional

The proposed study is a Phase II, feasibility, randomized controlled preference based study. This will be conducted in Vancouver and Toronto and includes breast and colorectal cancers.

NCT ID: NCT05364489 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer

Start date: June 15, 2022
Phase: Phase 2
Study type: Interventional

This study is a single-arm, prospective, open-label observational clinical study to evaluate the efficacy and safety of Bevacizumab combined with Oxaliplatin and TAS-102 in patients with advanced unresectable rectal cancer.